Uncategorized

David is currently a Managing Director of VIMAC Milestone Medica, LP, an early stage life science fund with VIMAC Ventures, LLC, a Boston based venture capital firm. The fund invests in the pharmaceutical, medical device and instrument sectors with start-up companies based on emerging technologies from leading academic institutions. At VIMAC, David participates in the formation and capitalization of companies, and working closely with the Fund’s portfolio companies, is involved in licensing transactions, collaborative research agreements and clinical trial activities.

Before joining VIMAC, David had over twenty-five years of business development and new venture experience including with Colgate-Palmolive in their corporate M&A group, as well as CFO of a Colgate subsidiary and Director of M&A, Industrial Products for Colgate’s billion dollar health care and industrial specialty subsidiary, The Kendall Company. At Kendall, David developed and implemented a strategic growth plan through acquisition, and later went on to start up and run an in-house industrial polymer membrane business, which he grew, spun off and successfully sold to a large multinational company. Most recently, before joining VIMAC, David was a General Partner with Wellfleet Investments in Boston, a private equity placement firm that developed a portfolio of emerging life science technologies from leading medical research institutions. While at Wellfleet, he also served as CEO of a medical clinic established by the firm based on an advanced gastrointestinal rehabilitation therapy developed at a Harvard teaching hospital.

David is a graduate of Syracuse University (’70, BA, Political Science) and is a member of the Board of Visitors for SU’s College of Arts and Sciences. He holds an MBA from Pace University. He lives in Newton, MA with his wife and two daughters.

Mr. Lyons has over twenty years of experience in the medical device industry. Graduating from Syracuse University in 1986 with a BSME degree and specializing in biomechanics, Mr. Lyons has held several positions with medical implant companies and holds numerous orthopedic and medical device patents.

1986 Mr. Lyons was a Development Engineer with Osteonics Corp, now known as Stryker Orthopedics (SYK) where he contributed to the company’s total hip group. Mr. Lyons joined Exactech Inc. (EXAC) in 1989 as its first engineering manager for the starting Orthopedics Company. While there, Mr. Lyons developed the company’s first porous coated total hip system. Along with product development, Mr. Lyons was responsible for establishing many of the company’s operating systems in Quality Control, Regulatory, and Manufacturing Engineering.

By the early 1990s Mr. Lyons re-joined his brother, William Lyons III, as Vice President of their family’s orthopedic manufacturing business. Mr. Lyons helped the business his father founded become a leader in endoscopic instrument development and orthopedic implant manufacturing until it was acquired by Image Guided Systems.

In 1996 Mr. Lyons co-founded Blackstone Medical, Inc. As President and CEO, Mr. Lyons grew the company’s sales from zero to $92 million in less than ten years until it was acquired by Orthofix International (OFIX). In that time, the company introduced over twenty instrument and implant systems, in Class I, II, and III, throughout the USA and in over thirty countries around the world.

Departments of Biomedical Engineering and Chemistry, Boston University, Boston, MA

mgrin@bu.edu   http://people.bu.edu/mgrin

Mark W. Grinstaff is a Professor of Biomedical Engineering, Chemistry, Materials Science and Engineering, and Pharmacology and Experimental Therapeutics at Boston University and a College of Engineering Distinguished Faculty Fellow. Mark received his Ph.D. from the University of Illinois under the mentorship of Professor Kenneth S. Suslick and was an NIH postdoctoral fellow at the California Institute of Technology with Professor Harry B. Gray. Mark’s awards include the ACS Nobel Laureate Signature Award, NSF Career Award, Pew Scholar in the Biomedical Sciences, Camille Dreyfus Teacher-Scholar, Alfred P. Sloan Research Fellowship, the Edward M. Kennedy Award for Health Care Innovation, and a Fellow of the National Academy of Inventors. He has published more than 190 peer-reviewed manuscripts and given more than 250 oral presentations. His students and fellows have given more than 100 oral presentations and 300 posters. He is a co-founder of four companies that are commercializing his ideas, and he has four products being sold and used in the clinic. His current research activities involve the synthesis of new macromolecules and amphiphiles, self-assembly chemistry, imaging contrast agents, drug delivery, and wound repair.

For a complete list of past and current research projects and a CV (126 pages) please visit his website:  http://people.bu.edu/mgrin

MRG alum Xiaofan Luo, President of Polymakr, along with Ryan Mather, Chief Designer invent new materials for 3D printing. https://www.kickstarter.com/projects/1981875718/polymakr-entirely-new-materials-for-desktop-3d-pri

Welcome to the Interactive Biomaterials REU Program.

2014 REU Program Information: Link

June 1, 2014 – August 8, 2014
Syracuse Biomaterials Institute
Syracuse University – Syracuse, New York

Faculty located on the campuses of Syracuse University, SUNY ESF, SUNY Upstate Medical University and  Syracuse VA Medical Center

APPLICATION, LETTERS OF RECOMMENDATION AND TRANSCRIPT MUST BE RECEIVED BY FEBRUARY 15, 2014

Program Highlights

Eligibility: Undergraduate students majoring in the following disciplines: Engineering, Chemistry, Biology or Physics with an interest in Biomaterials Science. Most Students will have completed their junior year, although talented students with less experience will be considered for acceptance in the program. Students must be U.S. Citizen or Permanent Resident.

Stipend: All participants will receive a stipend of $5400 and on-campus housing at no additional expense.

Possible Research Areas: Students have the opportunity to do research in any of the following areas: Understanding bacteria-material interactions by surface engineering; Functionalization of biomimetic interfaces via engineered proteins; Control of Natural Polymers for Drug Delivery; 2D and 3D Active Cell Culture; Neurite Outgrowth on Substrates with Modulus Gradients; Smart Drug Release: Furanone release from a shape memory hydrogel; Electrochemical Atomic Force Microscopy of Cell-Surface Interactions

HOW TO APPLY:

Application

• Complete the application form, which can either be completed online, or you can download, print, and mail in a hard copy.
• The application includes a personal statement (one page) describing your career goals in scientific research and why you wish to participate in this program. For the online version, you may find it easier to compose the personal statement by using a word processor, and then copy/paste it into the form.

Online: Print a copy of the online form for your records, check the box indicating that you agree to the stated conditions, and submit the form.

or

Hard Copy: Make a copy of the form for your records, sign the bottom indicating that you agree to the stated conditions, and send the form to our mailing address, or PDF and email a copy to kplow@syr.edu

Transcript(s)

Only official university transcript will be accepted. Please mail transcript to REU Program Director, Julie Hasenwinkel, C/O Syracuse Biomaterials Institute, 318 Bowne Hall, Syracuse, NY 13244-1200

Letters of Recommendation:

Obtain two letters of recommendation from faculty members at your institution or elsewhere. These persons should be familiar with your academic and/or research abilities and should be able to judge whether you are suited for undergraduate research. Please contact your references prior to submitting your application. References may send their letters of recommendation (hard copy) directly to Julie Hasenwinkel or can email a PDF letter to Karen Low (kplow@syr.edu)